Rep. Gilbert Ray Cisneros, Jr. Sells Off Boston Scientific Corporation (NYSE:BSX) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on July 02nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on June 5th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of The Descartes Systems Group (NASDAQ:DSGX) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Texas Roadhouse (NASDAQ:TXRH) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Texas Capital Bancshares (NASDAQ:TCBI) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Microchip Technology (NASDAQ:MCHP) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 6/30/2026.

Boston Scientific Stock Down 0.1%

NYSE:BSX traded down $0.05 during trading hours on Friday, reaching $45.09. The company’s stock had a trading volume of 26,336,601 shares, compared to its average volume of 20,716,750. The company has a market cap of $67.01 billion, a price-to-earnings ratio of 18.86, a price-to-earnings-growth ratio of 0.86 and a beta of 0.58. Boston Scientific Corporation has a one year low of $42.25 and a one year high of $109.50. The business’s 50-day moving average is $50.99 and its 200-day moving average is $69.43. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period last year, the company earned $0.75 earnings per share. The business’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific announced that its board has initiated a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its shares are undervalued.

Institutional Trading of Boston Scientific

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BSX. CX Institutional boosted its holdings in Boston Scientific by 20.5% during the second quarter. CX Institutional now owns 11,407 shares of the medical equipment provider’s stock valued at $487,000 after purchasing an additional 1,942 shares in the last quarter. Miller Global Investments LLC bought a new position in shares of Boston Scientific during the 2nd quarter worth approximately $369,000. Basecamp Wealth Advisors LLC boosted its stake in Boston Scientific by 45.5% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 3,740 shares of the medical equipment provider’s stock valued at $235,000 after buying an additional 1,170 shares in the last quarter. Ballast Advisors LLC bought a new stake in Boston Scientific in the first quarter valued at $62,000. Finally, Lombard Odier Asset Management Europe Ltd grew its position in Boston Scientific by 5.7% in the first quarter. Lombard Odier Asset Management Europe Ltd now owns 151,463 shares of the medical equipment provider’s stock valued at $9,504,000 after acquiring an additional 8,184 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares in the company, valued at $99,987.30. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Edward J. Ludwig bought 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director owned 25,359 shares in the company, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders purchased 9,800 shares of company stock valued at $554,012. 0.34% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BSX. Piper Sandler restated an “overweight” rating and set a $65.00 price target on shares of Boston Scientific in a report on Friday, June 12th. Needham & Company LLC reiterated a “buy” rating and set a $77.00 target price on shares of Boston Scientific in a research note on Monday, May 18th. The Goldman Sachs Group set a $71.00 price target on shares of Boston Scientific in a report on Thursday, May 28th. Robert W. Baird set a $70.00 price target on shares of Boston Scientific in a research report on Thursday, May 28th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $83.36.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.